FAM104A Inhibitors

Wortmannin and LY294002 are phosphoinositide 3-kinase (PI3K) inhibitors that could alter the activity of proteins regulated by PI3K signaling. PD98059 and U0126 inhibit MEK, a kinase in the MAPK/ERK pathway, which is a common signaling cascade involved in cell proliferation and differentiation. SP600125 and SB203580 are inhibitors of JNK and p38 MAPK, respectively, which are involved in cellular stress responses and inflammation.

Rapamycin is an mTOR inhibitor, influencing cell growth and proliferation, while Axitinib targets the VEGF receptors, which could affect angiogenesis and thereby impact proteins that play a role in this process. Dasatinib is a broad-spectrum Src kinase inhibitor that could affect various signaling pathways, and ZM-447439 inhibits Aurora kinases, which are critical for cell division. Palbociclib targets cyclin-dependent kinases 4 and 6 (CDK4/6), which are important for cell cycle regulation. ABT-199 inhibits Bcl-2, a protein that prevents apoptosis, thereby potentially affecting proteins involved in cell survival processes.